EP Patent

EP3459544A1 — Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione

Assigned to Celgene Corp · Expires 2019-03-27 · 7y expired

What this patent protects

Polymorphic form of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms and uses of such polymorphic forms and compositions in methods of treatment are also disclosed.

USPTO Abstract

Polymorphic form of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms and uses of such polymorphic forms and compositions in methods of treatment are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3459544A1
Jurisdiction
EP
Classification
—
Expires
2019-03-27
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.